MENU
+Compare
URGN
Stock ticker: NASDAQ
AS OF
Sep 26 closing price
Price
$18.34
Change
+$1.08 (+6.26%)
Capitalization
848.48M

URGN UroGen Pharma Ltd Forecast, Technical & Fundamental Analysis

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers... Show more

Industry: #Biotechnology
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for URGN with price predictions
Sep 26, 2025

URGN in +4.43% Uptrend, rising for three consecutive days on September 18, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where URGN advanced for three days, in of 263 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 65 cases where URGN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 151 cases where URGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 19, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on URGN as a result. In of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

URGN moved below its 50-day moving average on September 19, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for URGN crossed bearishly below the 50-day moving average on September 23, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where URGN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

URGN broke above its upper Bollinger Band on September 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. URGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (16.234) is normal, around the industry mean (19.823). P/E Ratio (0.000) is within average values for comparable stocks, (53.778). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.098). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (9.560) is also within normal values, averaging (349.540).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. URGN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

URGN is expected to report earnings to fall 38.72% to -64 cents per share on November 17

UroGen Pharma Ltd URGN Stock Earnings Reports
Q3'25
Est.
$-0.64
Q2'25
Missed
by $0.22
Q1'25
Missed
by $0.13
Q4'24
Missed
by $0.03
Q3'24
Beat
by $0.27
The last earnings report on August 07 showed earnings per share of -104 cents, missing the estimate of -82 cents. With 1.20M shares outstanding, the current market capitalization sits at 848.48M.
A.I. Advisor
published General Information

General Information

a developer of therapies for urological pathologies

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
400 Alexander Park Drive
Phone
+1 646 768-9780
Employees
201
Web
https://www.urogen.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
NQVRX62.090.56
+0.91%
Nuveen Multi Cap Value I
MSFRX20.150.13
+0.65%
MFS Total Return A
ACFNX82.560.45
+0.55%
American Century Focused Dynamic Gr R6
AIGGX17.510.06
+0.34%
Aristotle Growth Equity I-2
TEEAX11.09-0.01
-0.09%
RBC Small Cap Core A

URGN and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with AIM. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then AIM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
+6.26%
AIM - URGN
39%
Loosely correlated
-6.94%
ETNB - URGN
38%
Loosely correlated
N/A
SCPH - URGN
36%
Loosely correlated
+0.71%
ATXS - URGN
35%
Loosely correlated
+2.10%
PHAT - URGN
35%
Loosely correlated
+1.03%
More